<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258739</url>
  </required_header>
  <id_info>
    <org_study_id>TAX_ES1_209</org_study_id>
    <nct_id>NCT00258739</nct_id>
  </id_info>
  <brief_title>Docetaxel in Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II, Randomized Study With Docetaxel-gemcitabine Followed by Radiotherapy vs Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) Followed by Docetaxel-gemcitabine Versus Docetaxel-gemcitabine Followed by Concomitant Treatment (Radiotherapy and Carboplatine-docetaxel) in Stage III NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

        -  To classify the 2 study groups, according to the tumoral response.

      Secondary objectives:

        -  To evaluate the percentage of focused control per year.

        -  To calculate the time until progression.

        -  To evaluate the safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate in each arm measured according to RECIST criteria</measure>
    <time_frame>Throughout the whole study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of local-regional control within a year</measure>
    <time_frame>Throughout the first year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression defined as the period of time elapsed between the randomization date and the progression or death date</measure>
    <time_frame>Throughout the whole study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity measured by CALGB criteria and RTOG/EORTC criteria</measure>
    <time_frame>Throughout the whole study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global surveillance measured as the period of time elapsed between randomization and death date.</measure>
    <time_frame>Throughout the whole study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine</intervention_name>
    <description>Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Docetaxel + gemcitabine + carboplatin + radiotherapy</intervention_name>
    <description>Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non small cell lung cancer confirmed by histology or by cytology.

          -  IIIB stage, except if existing pleural discharge, upper cava vein syndrome or
             supraclavicular affectation

          -  General stage 0-1 at the ECOG scale

          -  Loss of weight less than 5% in the 3 previous months from diagnose.

          -  Pulmonary function and gasometry results: FEV1 &gt; 30% or 1 l, DLCO (diffusing capacity
             of the lung for carbon monoxide) &gt; 30%, PCO2 &lt; 45 mmHg and PO2 &gt; 60 mmHg.

          -  Normal medullar function (hemoglobin &gt; 11 g/dl, total WBC &gt; 1,5 x 10^9/l, platelets &gt;
             100 x 10^9/l)

          -  Appropriate renal and hepatic functions

          -  CTScan

          -  Anticonceptive method

          -  Available laboratory test (maximum 1 month before)

        Exclusion criteria:

          -  Pleural discharge, upper cava vein syndrome or supraclavicular affectation.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Mª Taboada</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2005</study_first_submitted>
  <study_first_submitted_qc>November 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

